A Trial of IW-3718 for 8 Weeks in Patients With Symptomatic Gastroesophageal Reflux Disease (GERD)

PHASE2CompletedINTERVENTIONAL
Enrollment

282

Participants

Timeline

Start Date

March 1, 2016

Primary Completion Date

April 26, 2017

Study Completion Date

April 26, 2017

Conditions
Gastroesophageal Reflux Disease
Interventions
DRUG

IW-3718

DRUG

Matching Placebo

DRUG

PPI

All participants were taking a standard dose QD PPI (dexlansoprazole, esomeprazole, esomeprazole magnesium, lansoprazole, omeprazole, pantoprazole, pantoprazole sodium sesquihydrate, rabeprazole or rabeprazole sodium) during the study.

Trial Locations (62)

10065

IW-3718 Investigator, New York

11021

IW-3718 Investigator, Great Neck

11023

IW-3718 Investigator, Great Neck

11415

IW-3718 Investigator, Kew Gardens

15243

IW-3718 Investigator, Pittsburgh

20815

IW-3718 Investigator, Chevy Chase

21215

IW-3718 Investigator, Baltimore

21401

IW-3718 Investigator, Annapolis

24073

IW-3718 Investigator, Christiansburg

24502

IW-3718 Investigator, Lynchburg

27612

IW-3718 Investigator, Raleigh

28801

IW-3718 Investigator, Asheville

29412

IW-3718 Investigator, Charleston

32129

IW-3718 Investigator, Port Orange

32720

IW-3718 Investigator, DeLand

33014

IW-3718 Investigator, Miami Lakes

33024

IW-3718 Investigator, Hollywood

33126

IW-3718 Investigator, Miami

33135

IW-3718 Investigator, Miami

33319

IW-3718 Investigator, Lauderdale Lakes

33458

IW-3718 Investigator, Jupiter

34452

IW-3718 Investigator, Inverness

36305

IW-3718 Investigator, Dothan

37232

IW-3718 Investigator, Nashville

37421

IW-3718 Investigator, Chattanooga

38138

IW-3718 Investigator, Germantown

42101

IW-3718 Investigator, Bowling Green

43213

IW-3718 Investigator, Columbus

44109

IW-3718 Investigator, Cleveland

45806

IW-3718 Investigator, Lima

48047

IW-3718 Investigator, Chesterfield

49519

IW-3718 Investigator, Wyoming

50325

IW-3718 Investigator, Clive

58103

IW-3718 Investigator, Fargo

71201

IW-3718 Investigator, Monroe

72117

IW-3718 Investigator, North Little Rock

73071

IW-3718 Investigator, Norman

73104

IW-3718 Investigator, Oklahoma City

77098

IW-3718 Investigator, Houston

78209

IW-3718 Investigator, San Antonio

78229

IW-3718 Investigator, San Antonio

79905

IW-3718 Investigator, El Paso

84092

IW-3718 Investigator, Sandy City

84405

IW-3718 Investigator, South Ogden

85018

IW-3718 Investigator, Phoenix

85710

IW-3718 Investigator, Tucson

85712

IW-3718 Investigator, Tucson

85741

IW-3718 Investigator, Tucson

89128

IW-3718 Investigator, Las Vegas

89511

IW-3718 Investigator, Reno

90638

IW-3718 Investigator, La Mirada

91345

IW-3718 Investigator, Mission Hills

91910

IW-3718 Investigator, Chula Vista

92123

IW-3718 Investigator, San Diego

92660

IW-3718 Investigator, Newport Beach

92801

IW-3718 Investigator, Anaheim

94612

IW-3718 Investigator, Oakland

95608

IW-3718 Investigator, Carmichael

95821

IW-3718 Investigator, Sacramento

06010

IW-3718 Investigator, Bristol

06708

IW-3718 Investigator, Waterbury

08234

IW-3718 Investigator, Egg Harbor

Sponsors
All Listed Sponsors
lead

Ironwood Pharmaceuticals, Inc.

INDUSTRY

NCT02637557 - A Trial of IW-3718 for 8 Weeks in Patients With Symptomatic Gastroesophageal Reflux Disease (GERD) | Biotech Hunter | Biotech Hunter